Angiotensinogen genotype, sodium reduction, weight loss, and prevention of hypertension: Trials of hypertension prevention, phase II

Hypertension

Volumn 32, Issue 3, 1998, Pages 393-401

  Hunt, Steven C ^a   Cook, Nancy R ^b   Oberman, Albert ^c   Cutler, Jeffrey A ^d   Hennekens, Charles H ^b   Allender, P Scott ^d   Walker, W Gordon ^e   Whelton, Paul K ^f   Williams, Roger R ^a  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c University of Alabama at Birmingham   (United States)

^d NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^e JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f TULANE UNIVERSITY   (United States)

Author keywords

Blood pressure; Clinical trials; Genetics; Interaction; Prospective study; Renin

Indexed keywords

ANGIOTENSINOGEN; SODIUM;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; FEMALE; GENOTYPE; HUMAN; HYPERTENSION; INCIDENCE; MAJOR CLINICAL STUDY; MALE; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SODIUM RESTRICTION; WEIGHT REDUCTION;

EID: 0031656257     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.HYP.32.3.393     Document Type: Article

References (33)

1. Jeunemaitre X, Soubrier F, Kotelevtsev Y, Lifton RP, Williams CS, Charru A, Hunt SC, Hopkins PN, Williams RR, Lalouel JM, Corvol P. Molecular basis of human hypertension: role of angiotensinogen. Cell. 1992;71:169-180.
2. Caulfield M, Lavender P, Farrall M, Munroe P, Lawson M, Turner P, Clark AJL. Linkage of the angiotensinogen gene to essential hypertension. N Engl J Med. 1994;330:1629-1633.
3. Jeunemaitre X, Inoue I, Williams C, Charru A, Tichet J, Powers M, Sharma AM, Gimenez-Roqueplo A-P, Hata A, Corvol P, Lalouel J-M. Haplotypes of angiotensinogen in essential hypertension. Am J Hum Genet. 1997;60:1448-1460.
4. Fornage M, Turner ST, Sing CF, Boerwinkle E. Variation at the M235T locus of the angiotensinogen gene and essential hypertension: a population-based case-control study from Rochester, Minnesota. Hum Genet. 1995;96:295-300.
5. Rotimi C, Morrison L, Cooper R, Oyejide C, Effiong E, Ladipo M, Osotemihen B, Ward R. Angiotensinogen gene in human hypertension: lack of an association of the 235T allele among African Americans. Hypertension. 1994;24:591-594.
6. Forrester T, McFarlane-Anderson N, Bennet F, Wilks R, Puras A, Cooper R, Rotimi C, Durazo R, Tewksbury D, Morrison L. Angiotensinogen and blood pressure among blacks: findings from a community survey in Jamaica. J Hypertens. 1996;14:315-321.
7. Inoue I, Nakajima T, Williams CS, Quackenbush J, Puryear R, Powers M, Cheng T, Ludwig EH, Sharma AM, Hata A, Jeunemaitre X, Lalouel J-M. A nucleotide substitution in the promoter of human angiotensinogen is associated with essential hypertension and affects basal transcription in vitro. J Clin Invest. 1997;99:1786-1797.
8. Campbell DJ, Habener JF. Angiotensinogen is expressed and differentially regulated in multiple tissues of the rat. J Clin Invest. 1986;78: 1427-1431.
9. Kim H-S, Krege JH, Kluckman KD, Hagaman JR, Hodgin JB, Best CF, Jennette JC, Coffman TM, Maeda N, Smithies O. Genetic control of blood pressure and the angiotensinogen locus. Proc Natl Acad Sci U S A. 1995;92:2735-2739.
10. Walker WG, Whelton PK, Saito H, Russell RP, Hermann J. Relation between blood pressure and renin, renin substrate, angiotensin II, aldosterone and urinary sodium and potassium in 574 ambulatory subjects. Hypertension. 1979;1:287-291.
11. Manatunga AK, Jones JJ, Pratt JH. Longitudinal assessment of blood pressures in Black and White children. Hypertension. 1993;22:84-89.
12. Ménard J, El Amrani A-IK, Savoie F, Bouhnik J. Angiotensinogen: an attractive and underrated participant in hypertension and inflammation. Hypertension. 1991;18:705-706.
13. Gardes J, Bouhnik J, Clauser E, Corvol P, Ménard J. Role of angiotensinogen in blood pressure homeostasis. Hypertension. 1982;4:185-189.
14. Schunkert H, Hense H-W, Gimenez-Roqueplo A, Stieber J, Keil U, Riegger GAJ, Jeunemaitre X. The angiotensinogen T235 variant and the use of antihypertensive drugs in a population-based cohort. Hypertension. 1997;29:628-633.
15. Hall JE. Renal and cardiovascular mechanisms of hypertension in obesity. Hypertension. 1994;23:381-394.
16. Hebert PR, Bolt RJ, Borhani NO, Cook NR, Cohen JD, Cutler JA, Hollis JF, Kuller LH, Lasser NL, Oberman A, Miller ST, Morris C, Whelton PK. for the trials of hypertension prevention (TOHP) collaborative research group: design of a multicenter trial to evaluate long-term lifestyle intervention in adults with high-normal blood pressure levels: Trials of Hypertension Prevention (Phase II). Ann Epidemiol. 1995;5:130-139.
17. The Trials of Hypertension Prevention Collaborative Research Group. Effects of weight loss and sodium reduction intervention on blood pressure and hypertension incidence in overweight people with high-normal blood pressure. Arch Intern Med. 1997;157:657-667.
18. Bloem LJ, Manatunga AK, Tewksbury DA, Pratt JH. The serum angiotensinogen concentration and variants of the angiotensinogen gene in white and black children. J Clin Invest. 1995;95:948-953.
19. 18a. Cook NR, Cohen J, Hebert P, Taylor JO, Hennekens CH. Implications of small reductions in diastolic blood pressure for primary prevention. Arch Intern Med. 1995;155:701-709.
20. Pickering TG. Lessons from the trials of hypertension prevention, phase II: energy intake is more important than dietary sodium in the prevention of hypertension. Arch Intern Med. 1997;157:596-597.
21. Grobbee DE, Hofman A. Does sodium restriction lower blood pressure? BMJ. 1986;293:27-29.
22. Cutler JA, Follmann D, Allender PS. Randomized trials of sodium reduction: an overview. Am J Clin Nutr. 1997;65(suppl 2):643S-651S.
23. Geleijnse JM, Hofman A, Witteman JCM, Hazebroek AAJM, Valkenburg HA, Grobbee DE. Long-term effects of neonatal sodium restriction on blood pressure. Hypertension. 1997;29:913-917.
24. Denton D, Weisinger R, Mundy NI, Wickings EJ, Dixson A, Moisson P, Pingard AM, Shade R, Carey D, Ardaillou R, Paillard F, Chapman J, Thillet J, Michel JB. The effect of increased salt intake on blood pressure of chimpanzees. Nat Med. 1995;1:1009-1014.
25. Luft FC, Grim CE, Higgins JT, Weinberger MH. Differences in response to sodium administration in normotensive white and black subjects. J Lab Clin Med. 1977;90:555-562.
26. Rocchini AP, Key J, Bordie D, Chico R, Moorehead C, Katch V, Martin M. The effect of weight loss on the sensitivity of blood pressure to sodium in obese adolescents. N Engl J Med. 1989;321:580-585.
27. Granger JP, West D, Scott J. Abnormal pressure natriuresis in the dog model of obesity-induced hypertension. Hypertension. 1994;23(suppl I):I-8-I-11.
28. Suzuki H, Ikenaga H, Hayashida T, Otsuka K, Kanno Y, Ohno Y, Ikeda H, Saruta T. Sodium balance and hypertension in obese and fatty rats. Kidney Int. 1996;55:S150-S153.
29. Hall JE. Control of sodium excretion by angiotensin: intrarenal mechanisms and blood pressure regulation. Am J Physiol. 1986;250:R960-R972.
30. Hopkins PN, Lifton RP, Hollenberg NK, Jeunemaitre X, Hallouin M-C, Skuppin J, Williams CS, Dluhy RG, Lalouel J-M, Williams RR, Williams GH. Blunted renal vascular response to angiotensin II is associated with a common variant of the angiotensinogen gene and obesity. J Hypertens. 1996;14:199-207.
31. Eggena P, Sowers JR, Maxwell MH, Barrett JD, Golub MS. Hormonal correlates of weight loss associated with blood pressure reduction. Clin Exp Hypertens. 1991;13:1447-1456.
32. Frederich RC, Jr, Kahn BB, Peach MJ, Flier JS. Tissue-specific nutritional regulation of angiotensinogen in adipose tissue. Hypertension. 1992;19:339-344.
33. The Sixth Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med. 1997;157:2413-2446.